drugset / Trial / NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2026-06-15
- Primary completion
- 2028-10-31
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adbrelimab | Unknown | — | — |
| Subject | Almonertinib | Small molecule | — | — |
| Subject | HS-20122 | Unknown | — | — |